Literature DB >> 25099712

US incentive scheme for neglected diseases: a good idea gone wrong?

Peter Doshi.   

Abstract

Mesh:

Substances:

Year:  2014        PMID: 25099712     DOI: 10.1136/bmj.g4665

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  5 in total

Review 1.  Chagas Disease in the United States: a Public Health Approach.

Authors:  Caryn Bern; Louisa A Messenger; Jeffrey D Whitman; James H Maguire
Journal:  Clin Microbiol Rev       Date:  2019-11-27       Impact factor: 26.132

Review 2.  Essential medicines for universal health coverage.

Authors:  Veronika J Wirtz; Hans V Hogerzeil; Andrew L Gray; Maryam Bigdeli; Cornelis P de Joncheere; Margaret A Ewen; Martha Gyansa-Lutterodt; Sun Jing; Vera L Luiza; Regina M Mbindyo; Helene Möller; Corrina Moucheraud; Bernard Pécoul; Lembit Rägo; Arash Rashidian; Dennis Ross-Degnan; Peter N Stephens; Yot Teerawattananon; Ellen F M 't Hoen; Anita K Wagner; Prashant Yadav; Michael R Reich
Journal:  Lancet       Date:  2016-11-08       Impact factor: 79.321

Review 3.  Why miltefosine-a life-saving drug for leishmaniasis-is unavailable to people who need it the most.

Authors:  Temmy Sunyoto; Julien Potet; Marleen Boelaert
Journal:  BMJ Glob Health       Date:  2018-05-03

4.  Creative use of the priority review voucher by public and not-for-profit actors delivers the first new FDA-approved treatment for river blindness in 20 years.

Authors:  Piero L Olliaro; Annette C Kuesel; Christine M Halleux; Mark Sullivan; John C Reeder
Journal:  PLoS Negl Trop Dis       Date:  2018-11-15

5.  Antiparasitic Drugs in the United States-Two Roads to High Prices.

Authors:  Arman A Shahriar; Jonathan D Alpern
Journal:  Front Sociol       Date:  2020-10-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.